This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)

Tipranks - Tipranks - Fri Jun 12, 3:40AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE).

Introducing TipRanks MCP for Agents

Crispr Therapeutics AG (CRSP)

Morgan Stanley analyst Terence Flynn upgraded Crispr Therapeutics AG to Hold today and set a price target of $60.00. The company’s shares closed last Wednesday at $49.44.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.7% and a 57.2% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Vertex Pharmaceuticals, and Intellia Therapeutics. ;'>

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $73.85, a 43.6% upside from current levels. In a report issued on June 5, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $51.00 price target.

See the top stocks recommended by analysts >>

Hinge Health, Inc. Class A (HNGE)

In a report released today, Ryan Daniels from William Blair reiterated a Buy rating on Hinge Health, Inc. Class A. The company’s shares closed last Wednesday at $62.06, close to its 52-week high of $66.55.

According to TipRanks.com, Daniels is a 2-star analyst with an average return of 0.2% and a 42.5% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Pediatrix Medical Group, Lifestance Health Group, and Alignment Healthcare. ;'>

Currently, the analyst consensus on Hinge Health, Inc. Class A is a Strong Buy with an average price target of $70.55, an 8.3% upside from current levels. In a report issued on June 5, TipRanks – xAI also upgraded the stock to Buy with a $70.00 price target.

Read More on CRSP:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).